Neuronetics to Report First Quarter 2021 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

MALVERN, Pa., April 20, 2021 – Neuronetics, a commercial-stage medical technology company, announced plans to release its first quarter financial results before market open on May 4, 2021. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time the same day. The call will be available via webcast on the company's investor relations website. Neuronetics specializes in products for psychiatric disorders, notably the NeuroStar® Advanced Therapy System, cleared by the FDA for treating major depressive disorder.

MALVERN, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter financial and operating results prior to market open on Tuesday, May 4, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 8667667, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.

Investor Contact:

Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

What date will Neuronetics release its Q1 results for 2021?

Neuronetics plans to release its first quarter financial results on May 4, 2021.

What time is the Neuronetics conference call on May 4, 2021?

The conference call is scheduled for 8:30 a.m. Eastern Time on May 4, 2021.

How can I listen to the Neuronetics conference call?

You can listen to the Neuronetics conference call via webcast on their investor relations website.

What is the focus of Neuronetics as a medical technology company?

Neuronetics focuses on developing products that enhance the quality of life for patients suffering from psychiatric disorders.

What product does Neuronetics offer for treating depression?

Neuronetics offers the NeuroStar® Advanced Therapy System, which uses transcranial magnetic stimulation for major depressive disorder.